Burch
989348

```
=> d l3 que stat
L1                STR
```






```
VAR G1=H/ME
REP G2=(1-20) A
VAR G3=16/20
VAR G4=H/C/SI
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  22

STEREO ATTRIBUTES: NONE
L3          759 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED  19478 ITERATIONS                          759 ANSWERS
SEARCH TIME: 00.00.11


=> e adenylyl cyclase/cn 5
E1            1     ADENYLYL (.BETA.,.GAMMA.-METHYLENE)DIPHOSPHONATE/CN
E2            1     ADENYLYL .BETA.,.GAMMA.-IMIDODIPHOSPHATE/CN
E3            1 --> ADENYLYL CYCLASE/CN
E4            1     ADENYLYL CYCLASE (AEROMONAS HYDROPHILA STRAIN 218 GENE CYAA
                    ISOENZYME 1)/CN
E5            1     ADENYLYL CYCLASE (DOG CLONE 6/27 HEART ISOFORM VI REDUCED)/C
                    N

=> s e3;d ide can;e fibroproliferative vasculopathy/cn 5
L4            1 "ADENYLYL CYCLASE"/CN


L4   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2002 ACS
RN   9012-42-4  REGISTRY
CN   Cyclase, adenylate (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Adenyl cyclase
CN   Adenylate cyclase
CN   Adenylyl cyclase
CN   E.C. 4.6.1.1

Searched by: Mary Hale 308-4258 CM-1 1E01
```

```
MF   Unspecified
CI   MAN
LC   STN Files:   ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
       CA, CABA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, CSCHEM, EMBASE,
       IFICDB, IFIPAT, IFIUDB, IPA, PROMT, TOXCENTER, USPAT2, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
          18802 REFERENCES IN FILE CA (1967 TO DATE)
             42 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
          18810 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE   1:  137:18214

REFERENCE   2:  137:17453

REFERENCE   3:  137:16033

REFERENCE   4:  137:16005

REFERENCE   5:  137:4315

REFERENCE   6:  137:3303

REFERENCE   7:  137:3300

REFERENCE   8:  137:3294

REFERENCE   9:  137:3287

REFERENCE  10:  137:1968


E1            1     FIBROPELLIN III (STRONGYLOCENTROTUS PURPURATUS CLONE R1 REDU
                    CED)/CN
E2            1     FIBROPLAST/CN
E3            0 --> FIBROPROLIFERATIVE VASCULOPATHY/CN
E4            1     FIBROPUR P 68/CN
E5            1     FIBROSIN (HUMAN PLACENTA REDUCED)/CN

=> fil medl,hcapl,embase,biosis,jicst;s l3 and (l4 or (adenylyl or
adenylate)(w)cyclase or 9012-42-4 or adenine nucleotide! or fibroprolif?
vasculopath? or fibro prolifer?(5a)vasculopath?)
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              150.62     150.83

FILE 'MEDLINE' ENTERED AT 10:20:32 ON 09 JUL 2002

FILE 'HCAPLUS' ENTERED AT 10:20:32 ON 09 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:20:32 ON 09 JUL 2002
COPYRIGHT (C) 2002 Elsevier Science B.V.  All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:20:32 ON 09 JUL 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'JICST-EPLUS' ENTERED AT 10:20:32 ON 09 JUL 2002
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

Searched by: Mary Hale 308-4258 CM-1 1E01
```

L5 0 FILE MEDLINE
L6 6 FILE HCAPLUS
L7 0 FILE EMBASE
L8 0 FILE BIOSIS
L9 0 FILE JICST-EPLUS

TOTAL FOR ALL FILES
L10 6 L3 AND (L4 OR (ADENYLYL OR ADENYLATE)(W) CYCLASE OR 9012-42-4 OR ADENINE NUCLEOTIDE! OR FIBROPROLIF? VASCULOPATH? OR FIBRO PROLIFER?(5A) VASCULOPATH?)

=> d 1-6 cbib abs hitstr

L10 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2002 ACS
2002:391715 Document No. 136:386348 Preparation of adenine based carbocyclic nucleosides as inhibitors of **adenylyl cyclase** and for treatment of patient's **fibroproliferative vasculopathy**
. Levy, Daniel E.; Marlowe, Charles; Kane-Maguire, Kim; Scarborough, Robert M. (Cor Therapeutics, Inc., USA). PCT Int. Appl. WO 2002040481 A2 20020523, 91 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US43294 20011120. PRIORITY: US 2000-PV249465 20001120.
GI



I

AB The present invention relates to derivs. and analogs of adenine I wherein, L and Y are independently alkylidene, oxyalkylidene, aminoalkylidene, A is a direct link or A is divalent member selected from the group consisting of Ph, thienyl, furanyl, pyrrolyl, indolyl, heterocycle; Z is (CH2)nC(O)NHOH, (CH2)nCOOH; n = 0-4; which inhibit **adenylyl cyclase** activity. The present invention also relates to a method of preventing and inhibiting a patient's **fibroproliferative vasculopathy** following vascular injury or a vascular surgical operation which includes administering to the patient, an effective amt. of a compd. according to the invention subsequent to a vascular injury, or subsequent to a vascular surgical operation, for one to two weeks after the injury or surgical operation, effective to treat or prevent a

patient's **fibroproliferative vasculopathy** such as chronic allograft rejection or vascular restenosis following vascular trauma. The present invention also relates to a method for measuring the inhibition of **adenylyl cyclase** activity and a method for treating congestive heart failure. Thus, (1S)-1-(9-adenenyl)-3-carboxy-3-cyclopentene was prepd. as inhibitor of **adenylyl cyclase** and for treatment of patient's **fibroproliferative vasculopathy** (no data).

IT **9012-42-4, Adenylyl cyclase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(prepn. of adenine based carbocyclic nucleosides as inhibitors of **adenylyl cyclase** and for treatment of patient's **fibroproliferative vasculopathy**)

RN 9012-42-4 HCAPLUS
CN Cyclase, adenylate (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **4323-13-1P 90973-36-7P 426226-30-4P 426226-31-5P 426226-32-6P 426226-33-7P 426226-34-8P**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of adenine based carbocyclic nucleosides as inhibitors of **adenylyl cyclase** and for treatment of patient's **fibroproliferative vasculopathy**)

RN 4323-13-1 HCAPLUS
CN 9H-Purine-9-heptanoic acid, 6-amino- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 90973-36-7 HCAPLUS
CN 9H-Purine-9-pentanoic acid, 6-amino- (9CI) (CA INDEX NAME)



RN 426226-30-4 HCAPLUS
CN 9H-Purine-9-butanamide, 6-amino-N-hydroxy- (9CI) (CA INDEX NAME)

Searched by: Mary Hale 308-4258 CM-1 1E01



RN 426226-31-5 HCAPLUS
CN 9H-Purine-9-pentanamide, 6-amino-N-hydroxy- (9CI) (CA INDEX NAME)



RN 426226-32-6 HCAPLUS
CN 9H-Purine-9-hexanamide, 6-amino-N-hydroxy- (9CI) (CA INDEX NAME)



RN 426226-33-7 HCAPLUS
CN 9H-Purine-9-heptanamide, 6-amino-N-hydroxy- (9CI) (CA INDEX NAME)



RN 426226-34-8 HCAPLUS
CN 9H-Purine-9-hexanoic acid, 6-amino- (9CI) (CA INDEX NAME)



Searched by: Mary Hale 308-4258 CM-1 1E01

IT **41785-06-2P 70259-15-3P 326797-58-4P**
359865-38-6P 426226-28-0P 426226-29-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of adenine based carbocyclic nucleosides as inhibitors of **adenylyl cyclase** and for treatment of patient's **fibroproliferative vasculopathy**)

RN 41785-06-2 HCAPLUS
CN 9H-Purine-9-butanoic acid, 6-amino-, ethyl ester (9CI) (CA INDEX NAME)



RN 70259-15-3 HCAPLUS
CN 9H-Purine-9-propanoic acid, 6-amino-, methyl ester (9CI) (CA INDEX NAME)



RN 326797-58-4 HCAPLUS
CN 9H-Purine-9-pentanoic acid, 6-amino-, methyl ester (9CI) (CA INDEX NAME)



RN 359865-38-6 HCAPLUS
CN 9H-Purine-9-heptanoic acid, 6-amino-, ethyl ester (9CI) (CA INDEX NAME)



RN 426226-28-0 HCAPLUS
CN 9H-Purine-9-hexanoic acid, 6-amino-, ethyl ester (9CI) (CA INDEX NAME)

Searched by: Mary Hale 308-4258 CM-1 1E01



RN 426226-29-1 HCAPLUS
CN 9H-Purine-9-propanamide, 6-amino-N-hydroxy- (9CI) (CA INDEX NAME)



L10 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2002 ACS
1993:117336 Document No. 118:117336 Characterization of membrane-bound and solubilized high-affinity binding sites for 5'-N-ethylcarboxamido[3H]adenosine from bovine cerebral cortex. Lorenzen, Anna; Nitsch-Kirsch, Monika; Vogt, Heidrun; Schwabe, Ulrich (Pharmakol. Inst., Univ. Heidelberg, Heidelberg, D-6900, Germany). J. Neurochem., 60(2), 745-51 (English) 1993. CODEN: JONRA9. ISSN: 0022-3042.

AB A high-affinity binding site for 5'-N-ethylcarboxamido[3H]adenosine ([3H]NECA) from bovine cerebral cortex has been characterized in its membrane-bound and solubilized state after gel filtration on Sepharose CL-6B. For detection of this site in membranes, it was necessary to remove metabolites with high affinities for this site enzymically, e.g., adenosine by addn. of adenosine deaminase and inosine by addn. of nucleoside phosphorylase. The pore-forming peptide antibiotic alamethicin further enhanced binding of [3H]NECA to this site in membranes. In contrast to adenosine receptors and the adenotin-like low-affinity binding protein, this novel site was extremely sensitive against treatment with the sulfhydryl alkylating agent N-ethylmaleimide. In competition expts., this site could be differentiated from adenosine receptors by its high affinity for **adenine nucleotides** and its lack of affinity for adenosine receptor antagonists. Inosine and its deriv. S-(4-nitrobenzyl)-6-thioinosine were relatively potent ligands with Ki values in the high nano- and low micromolar range, resp. Apparently, the high-affinity NECA binding site described previously in bovine striatum is not exclusively located in the striatum, but can also be detected in membrane prepns. and sol. exts. of bovine brain cortex.

IT **23918-98-1**, Eritadenine
RL: BIOL (Biological study)
(NECA binding affinity for, in cerebral cortex)

RN 23918-98-1 HCAPLUS
CN 9H-Purine-9-butanoic acid, 6-amino-.alpha.,.beta.-dihydroxy-, (.alpha.R,.beta.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by: Mary Hale 308-4258 CM-1 1E01



L10 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2002 ACS
1981:526666 Document No. 95:126666 Eritadenine: a new tool for investigation of the adenosine P site in plasma membranes of rat fat cells. Soechtig, E.; Trost, T. (Abt. Allg. Pharmakol., Med. Hochsch., Hannover, Fed. Rep. Ger.). Pharmacology, 23(2), 82-90 (English) 1981. CODEN: PHMGBN. ISSN: 0031-7012.
GI



I

AB Eritadenine (I) [**23918-98-1**] was investigated for its effects on **adenylate cyclase** [**9012-42-4**] activity of rat fat cell plasma membranes and on cyclic AMP [60-92-4] accumulation and lipolysis in isolated rat fat cells. In rat fat cell plasma membranes, a 50% inhibition of noradrenaline-stimulated **adenylate cyclase** was obtained at I and adenosine [58-61-7] concns. of 11.6 .mu.mol/L and 9.0 .mu.mol/L, resp. NaF-stimulated **adenylate cyclase** was inhibited at concns. of I lower than those of adenosine. Eritadenine Et ester [**28987-93-1**] was almost ineffective on **adenylate cyclase**. The inhibitory effect of I was resistant to adenosine deaminase. In isolated rat fat cells, I was completely ineffective to block noradrenaline-stimulated cyclic AMP accumulation or lipolysis stimulated by theophylline or adenosine deaminase. I may be an effector of the adenosine P site of fat cell plasma membranes.

IT **23918-98-1**
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(adenosine receptors of adipocyte cell membrane response to)

RN 23918-98-1 HCAPLUS
CN 9H-Purine-9-butanoic acid, 6-amino-.alpha.,.beta.-dihydroxy-, (.alpha.R,.beta.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by: Mary Hale 308-4258 CM-1 1E01



IT **28987-93-1**
RL: PRP (Properties)
(**adenylate cyclase** of adipocyte cell membrane in relation to)
RN 28987-93-1 HCAPLUS
CN 9H-Purine-9-butanoic acid, 6-amino-.alpha.,.beta.-dihydroxy-, ethyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **9012-42-4**
RL: BIOL (Biological study)
(of adipocyte cell membrane, eritadenine effect on, adenosine receptors in relation to)
RN 9012-42-4 HCAPLUS
CN Cyclase, adenylate (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L10 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2002 ACS
1979:80803 Document No. 90:80803 Regulation of the activity of malignant cell adenyl cyclase using the synthetic adenine derivative - adenyl-9-alanine. Gilev, A. P.; Lidaks, M. (USSR). Novosti Khimii Nukleozidov i Nukleotidov 157-8 From: Ref. Zh., Biol. Khim. 1978, Abstr. No. 20Ts1092 (Russian) 1978.
AB Title only translated.
IT **58845-56-0**
RL: BIOL (Biological study)
(**adenylate cyclase** stimulation and cAMP phosphodiesterase inhibition by, in neoplasm)
RN 58845-56-0 HCAPLUS
CN 9H-Purine-9-propanoic acid, .alpha.,6-diamino-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by: Mary Hale 308-4258 CM-1 1E01



IT **9012-42-4**
RL: PROC (Process)
(stimulation of, by adenylalanine in neoplasm)
RN 9012-42-4 HCAPLUS
CN Cyclase, adenylate (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L10 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2002 ACS
1975:25763 Document No. 82:25763 Inhibition of protein kinase and cyclic AMP phosphodiesterase by eritadenine isoamyl ester. Possible mechanism for its biphasic effects on cyclic AMP-dependent lipolysis, steroidogenesis, and amino acid uptake. Iwai, Hajime (Sch. Med., Chiba Univ., Chiba City, Japan). J. Biochem. (Tokyo), 76(2), 419-29 (English) 1974. CODEN: JOBIAO.
GI For diagram(s), see printed CA Issue.
AB The hypolipidemic compd. eritadenine isoamyl ester (I) [**33303-44-5**] inhibited theophylline [58-55-9]-induced lipolysis and potentiated epinephrine [51-43-4]-induced lipolysis in rat epididymal fats cell in vitro. Epinephrine stimulated lipolysis by activating **adenylate cyclase**: I inhibited cyclic AMP phosphodiesterase (E.C. 3.1.4.7) [9013-53-0] of fat cells, increased the rate of cyclic AMP [60-92-4] accumulation induced by epinephrine, and potentiated cyclic AMP- induced lipolysis. I also inhibited cyclic AMP-dependent protein kinase (E.C. 2.7.1.37) [9026-43-1] of fat cells, which activates lipase: this may be related to its inhibition of theophylline-induced lipolysis. I enhanced the action of low concn. (5 .times. 10-5-5 .times. 10-4 M) and suppressed the action of high concn. (10-3M) of dibutyryl cyclic AMP [362-74-3] on lipolysis, amino acid uptake by liver, and steroidogenesis by the adrenal glands.
IT **33303-44-5**
RL: BIOL (Biological study)
(lipolysis response to, cyclic AMP phosphodiesterase and protein kinase in relation to)
RN 33303-44-5 HCAPLUS
CN 9H-Purine-9-butanoic acid, 6-amino-.alpha.,.beta.-dihydroxy-, 3-methylbutyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Searched by: Mary Hale 308-4258 CM-1 1E01

L10 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2002 ACS
1974:67752 Document No. 80:67752 Potent magnesium-dependent inhibition of **adenylate cyclase** activity from guinea pig lung by adenosine and other 9-substituted adenines. Weinryb, Ira; Michel, Inge M. (Dep. Biochem, Pharmacol, Squibb Inst. Med. Res., Princeton, N. J., USA). Biochim. Biophys. Acta, 334(1), 218-25 (English) 1974. CODEN: BBACAQ.

AB The inhibition of **adenylate cyclase** (EC 4.6.1.1) from guinea pig lung by adenosine and a no. of 9-substituted adenines was Mg2+-dependent, the compds. being up to 13 times more potent at satg. or near satg. Mg2+ concns. (11.8mM) than at limiting (1.8mM) concns. Inhibition by adenine and 6-mercaptopurine did not show a Mg2+ dependence. The most potent inhibitors of cyclase activity at 11.8mM Mg2+ of the 9-substituted adenines tested were: 9-(5-methyl-2-tetrahydrofuryl)adenine (I50 = 8.mu.M), 9-(tetrahydro-2-furyl)adenine (I50 = 10.mu.M), 9-cyclopentyladenine (I50 = 20.mu.M), and 9-furfuryladenine (I50 = 26.mu.M). The inhibition of lung cyclase activity by 9-(tetrahydro-2-furyl)adenine was deduced to be hyperbolic noncompetitive at 1.8mM (Ki = 1.2 .times. 10-4M) and 11.8mM (Ki = 2.5 .times. 10-6M) Mg2+ from anal. of double-reciprocal plots; these plots showed a concave downward nonlinearity in the presence of inhibitor at both Mg2+ concns. This nonlinearity was eliminated under conditions where Mg2+ levels were never in excess of those of ATP. Hill plots of the inhibition by 9-(tetrahydro-2-furyl)adenine (and by adenosine) suggested that neg. cooperativity is involved in binding to the enzyme. The possibility that the Mg2+-dependence of inhibitory potency of adenosine and its analogs functions as a cellular control mechanism is discussed.

IT **23919-15-5**
RL: BIOL (Biological study)
(**adenylate cyclase** inhibition by, magnesium effect on)
RN 23919-15-5 HCAPLUS
CN 9H-Purine-9-butanoic acid, 6-amino-.alpha.,.beta.-dihydroxy- (9CI) (CA INDEX NAME)



IT **9012-42-4**
RL: BIOL (Biological study)
(inhibition of lung, by adenine derivs., magnesium effect on)
RN 9012-42-4 HCAPLUS
CN Cyclase, adenylate (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> fil caol;s l3

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	92.10	242.93
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.72	-3.72

Searched by: Mary Hale 308-4258 CM-1 1E01

FILE 'CAOLD' ENTERED AT 10:21:19 ON 09 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGlstRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L11 4 L3

=> d 1-4

L11 ANSWER 1 OF 4 CAOLD COPYRIGHT 2002 ACS
AN CA65:7178h CAOLD
TI Michael-type reactions with adenine
AU Lira, Emil P.; Huffman, C. W.
IT 711-64-8 **4244-47-7** 7051-59-4 7051-64-1 7051-65-2
7083-40-1 92503-72-5 94626-13-8

L11 ANSWER 2 OF 4 CAOLD COPYRIGHT 2002 ACS
AN CA63:18872g CAOLD
TI nonclassical antimetabolites - (XXII) simulation of 5'-phosphoribosyl binding (5) inhibition of succino-adenylate kinosynthetase by 6-mercapto-9-purinyl alkanoic acid derivs. of 4- and 5-aminosalicylic acid
AU Baker, Bernard R.; Tanna, P. M.
IT 2545-91-7 2646-81-3 3275-78-3 4323-00-6 4323-01-7 4323-02-8
4323-03-9 4323-04-0 4323-05-1 4323-06-2 4323-07-3 4323-08-4
4323-09-5 4323-10-8 4323-11-9 4323-12-0 **4323-13-1**
4323-17-5 4323-18-6 4323-19-7 4369-82-8 4369-84-0 4418-13-7
5187-88-2

L11 ANSWER 3 OF 4 CAOLD COPYRIGHT 2002 ACS
AN CA63:16350g CAOLD
TI 2-(.alpha.-hydroxybenzyl)benzimidazole analogs - (I) synthesis of 8-(.alpha.-hydroxybenzyl)purines, the diaza analogs of 2-(.alpha.-hydroxybenzyl)benzimidazole
AU Haggerty, William J., Jr.; Springer, R. H.; Cheng, C. C.
IT 2260-33-5 2836-31-9 4244-40-0 4244-41-1 4244-43-3 4244-44-4
4244-45-5 **4244-47-7** 4244-49-9 4244-51-3 4244-52-4
4244-53-5 4244-54-6 4244-55-7 4244-56-8 4244-58-0 4289-23-0
4289-25-2 4301-59-1 4367-64-0 4460-07-5 4460-08-6 4460-09-7
4460-10-0 4538-20-9 34397-00-7 97317-88-9 98882-63-4 99785-41-8

L11 ANSWER 4 OF 4 CAOLD COPYRIGHT 2002 ACS
AN CA60:4402g CAOLD
TI nonclassical antimetabolites - (XIII) simulation of the 5'-phosphoribosyl moiety of 5'-adenylic acid at the enzyme level by .omega.-carboxyalkyl and aralkyl groups attached to adenine
AU Baker, Bernard R.; Sachdev, H. S.
IT 3342-88-9 17756-30-8 28492-53-7 34397-01-8 34397-05-2 82222-85-3

Searched by: Mary Hale 308-4258 CM-1 1E01